世界の腫瘍誘発性骨軟化症市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Tumour-Induced Osteomalacia Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z5762
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、93ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品、ヘルスケア

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、腫瘍誘発性骨軟化症のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（医薬品、サプリメント、手術、その他）、用途別市場規模（検査室、骨スキャン、鑑別診断、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・腫瘍誘発性骨軟化症の市場動向
・企業の競争状況、市場シェア
・腫瘍誘発性骨軟化症の種類別市場規模（医薬品、サプリメント、手術、その他）
・腫瘍誘発性骨軟化症の用途別市場規模（検査室、骨スキャン、鑑別診断、その他）
・腫瘍誘発性骨軟化症の北米市場規模2016-2027（アメリカ、カナダ）
・腫瘍誘発性骨軟化症のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・腫瘍誘発性骨軟化症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・腫瘍誘発性骨軟化症の中南米市場規模2016-2027（メキシコ、ブラジル）
・腫瘍誘発性骨軟化症の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Kyowa Kirin、Taizhou Hisound Pharmaceutical、Zhejiang Garden Biochemical High-tech、Kingdomway Nutrition、Amgen、Forgo Pharmaceuticals、Abbott、Solvay、GE Healthcare、Siemens）
・結論

Tumour-induced osteomalacia or oncogenic osteomalacia is a rare paraneoplastic syndrome of bone which consist of osteomalacia or rickets induced by phosphaturic mesenchymal tumour (PMT). Tumour-induced osteomalacia diagnosed with an elevated level of blood fibroblast growth factor 23 (FGF23), phosphate and vitamin D-regulating hormone.

Market Analysis and Insights: Global Tumour-Induced Osteomalacia Market
The global Tumour-Induced Osteomalacia market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Tumour-Induced Osteomalacia market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Tumour-Induced Osteomalacia market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Tumour-Induced Osteomalacia market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Tumour-Induced Osteomalacia market.

Global Tumour-Induced Osteomalacia Scope and Market Size
Tumour-Induced Osteomalacia market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Tumour-Induced Osteomalacia market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Drugs
Supplements
Surgery
Others

Segment by Application
Laboratories
Bone Scan
Differential Diagnosis
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Kyowa Kirin
Taizhou Hisound Pharmaceutical
Zhejiang Garden Biochemical High-tech
Kingdomway Nutrition
Amgen
Forgo Pharmaceuticals
Abbott
Solvay
GE Healthcare

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumour-Induced Osteomalacia Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drugs
1.2.3 Supplements
1.2.4 Surgery
1.2.5 Others
1.3 Market by Application
1.3.1 Global Tumour-Induced Osteomalacia Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Laboratories
1.3.3 Bone Scan
1.3.4 Differential Diagnosis
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Tumour-Induced Osteomalacia Market Perspective (2016-2027)
2.2 Tumour-Induced Osteomalacia Growth Trends by Regions
2.2.1 Tumour-Induced Osteomalacia Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Tumour-Induced Osteomalacia Historic Market Share by Regions (2016-2021)
2.2.3 Tumour-Induced Osteomalacia Forecasted Market Size by Regions (2022-2027)
2.3 Tumour-Induced Osteomalacia Industry Dynamic
2.3.1 Tumour-Induced Osteomalacia Market Trends
2.3.2 Tumour-Induced Osteomalacia Market Drivers
2.3.3 Tumour-Induced Osteomalacia Market Challenges
2.3.4 Tumour-Induced Osteomalacia Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Tumour-Induced Osteomalacia Players by Revenue
3.1.1 Global Top Tumour-Induced Osteomalacia Players by Revenue (2016-2021)
3.1.2 Global Tumour-Induced Osteomalacia Revenue Market Share by Players (2016-2021)
3.2 Global Tumour-Induced Osteomalacia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Tumour-Induced Osteomalacia Revenue
3.4 Global Tumour-Induced Osteomalacia Market Concentration Ratio
3.4.1 Global Tumour-Induced Osteomalacia Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumour-Induced Osteomalacia Revenue in 2020
3.5 Tumour-Induced Osteomalacia Key Players Head office and Area Served
3.6 Key Players Tumour-Induced Osteomalacia Product Solution and Service
3.7 Date of Enter into Tumour-Induced Osteomalacia Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Tumour-Induced Osteomalacia Breakdown Data by Type
4.1 Global Tumour-Induced Osteomalacia Historic Market Size by Type (2016-2021)
4.2 Global Tumour-Induced Osteomalacia Forecasted Market Size by Type (2022-2027)

5 Tumour-Induced Osteomalacia Breakdown Data by Application
5.1 Global Tumour-Induced Osteomalacia Historic Market Size by Application (2016-2021)
5.2 Global Tumour-Induced Osteomalacia Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Tumour-Induced Osteomalacia Market Size (2016-2027)
6.2 North America Tumour-Induced Osteomalacia Market Size by Type
6.2.1 North America Tumour-Induced Osteomalacia Market Size by Type (2016-2021)
6.2.2 North America Tumour-Induced Osteomalacia Market Size by Type (2022-2027)
6.2.3 North America Tumour-Induced Osteomalacia Market Size by Type (2016-2027)
6.3 North America Tumour-Induced Osteomalacia Market Size by Application
6.3.1 North America Tumour-Induced Osteomalacia Market Size by Application (2016-2021)
6.3.2 North America Tumour-Induced Osteomalacia Market Size by Application (2022-2027)
6.3.3 North America Tumour-Induced Osteomalacia Market Size by Application (2016-2027)
6.4 North America Tumour-Induced Osteomalacia Market Size by Country
6.4.1 North America Tumour-Induced Osteomalacia Market Size by Country (2016-2021)
6.4.2 North America Tumour-Induced Osteomalacia Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Tumour-Induced Osteomalacia Market Size (2016-2027)
7.2 Europe Tumour-Induced Osteomalacia Market Size by Type
7.2.1 Europe Tumour-Induced Osteomalacia Market Size by Type (2016-2021)
7.2.2 Europe Tumour-Induced Osteomalacia Market Size by Type (2022-2027)
7.2.3 Europe Tumour-Induced Osteomalacia Market Size by Type (2016-2027)
7.3 Europe Tumour-Induced Osteomalacia Market Size by Application
7.3.1 Europe Tumour-Induced Osteomalacia Market Size by Application (2016-2021)
7.3.2 Europe Tumour-Induced Osteomalacia Market Size by Application (2022-2027)
7.3.3 Europe Tumour-Induced Osteomalacia Market Size by Application (2016-2027)
7.4 Europe Tumour-Induced Osteomalacia Market Size by Country
7.4.1 Europe Tumour-Induced Osteomalacia Market Size by Country (2016-2021)
7.4.2 Europe Tumour-Induced Osteomalacia Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Tumour-Induced Osteomalacia Market Size (2016-2027)
8.2 Asia-Pacific Tumour-Induced Osteomalacia Market Size by Type
8.2.1 Asia-Pacific Tumour-Induced Osteomalacia Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Tumour-Induced Osteomalacia Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Tumour-Induced Osteomalacia Market Size by Type (2016-2027)
8.3 Asia-Pacific Tumour-Induced Osteomalacia Market Size by Application
8.3.1 Asia-Pacific Tumour-Induced Osteomalacia Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Tumour-Induced Osteomalacia Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Tumour-Induced Osteomalacia Market Size by Application (2016-2027)
8.4 Asia-Pacific Tumour-Induced Osteomalacia Market Size by Region
8.4.1 Asia-Pacific Tumour-Induced Osteomalacia Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Tumour-Induced Osteomalacia Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Tumour-Induced Osteomalacia Market Size (2016-2027)
9.2 Latin America Tumour-Induced Osteomalacia Market Size by Type
9.2.1 Latin America Tumour-Induced Osteomalacia Market Size by Type (2016-2021)
9.2.2 Latin America Tumour-Induced Osteomalacia Market Size by Type (2022-2027)
9.2.3 Latin America Tumour-Induced Osteomalacia Market Size by Type (2016-2027)
9.3 Latin America Tumour-Induced Osteomalacia Market Size by Application
9.3.1 Latin America Tumour-Induced Osteomalacia Market Size by Application (2016-2021)
9.3.2 Latin America Tumour-Induced Osteomalacia Market Size by Application (2022-2027)
9.3.3 Latin America Tumour-Induced Osteomalacia Market Size by Application (2016-2027)
9.4 Latin America Tumour-Induced Osteomalacia Market Size by Country
9.4.1 Latin America Tumour-Induced Osteomalacia Market Size by Country (2016-2021)
9.4.2 Latin America Tumour-Induced Osteomalacia Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Tumour-Induced Osteomalacia Market Size (2016-2027)
10.2 Middle East & Africa Tumour-Induced Osteomalacia Market Size by Type
10.2.1 Middle East & Africa Tumour-Induced Osteomalacia Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Tumour-Induced Osteomalacia Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Tumour-Induced Osteomalacia Market Size by Type (2016-2027)
10.3 Middle East & Africa Tumour-Induced Osteomalacia Market Size by Application
10.3.1 Middle East & Africa Tumour-Induced Osteomalacia Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Tumour-Induced Osteomalacia Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Tumour-Induced Osteomalacia Market Size by Application (2016-2027)
10.4 Middle East & Africa Tumour-Induced Osteomalacia Market Size by Country
10.4.1 Middle East & Africa Tumour-Induced Osteomalacia Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Tumour-Induced Osteomalacia Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Kyowa Kirin
11.1.1 Kyowa Kirin Company Details
11.1.2 Kyowa Kirin Business Overview
11.1.3 Kyowa Kirin Tumour-Induced Osteomalacia Introduction
11.1.4 Kyowa Kirin Revenue in Tumour-Induced Osteomalacia Business (2016-2021)
11.1.5 Kyowa Kirin Recent Development
11.2 Taizhou Hisound Pharmaceutical
11.2.1 Taizhou Hisound Pharmaceutical Company Details
11.2.2 Taizhou Hisound Pharmaceutical Business Overview
11.2.3 Taizhou Hisound Pharmaceutical Tumour-Induced Osteomalacia Introduction
11.2.4 Taizhou Hisound Pharmaceutical Revenue in Tumour-Induced Osteomalacia Business (2016-2021)
11.2.5 Taizhou Hisound Pharmaceutical Recent Development
11.3 Zhejiang Garden Biochemical High-tech
11.3.1 Zhejiang Garden Biochemical High-tech Company Details
11.3.2 Zhejiang Garden Biochemical High-tech Business Overview
11.3.3 Zhejiang Garden Biochemical High-tech Tumour-Induced Osteomalacia Introduction
11.3.4 Zhejiang Garden Biochemical High-tech Revenue in Tumour-Induced Osteomalacia Business (2016-2021)
11.3.5 Zhejiang Garden Biochemical High-tech Recent Development
11.4 Kingdomway Nutrition
11.4.1 Kingdomway Nutrition Company Details
11.4.2 Kingdomway Nutrition Business Overview
11.4.3 Kingdomway Nutrition Tumour-Induced Osteomalacia Introduction
11.4.4 Kingdomway Nutrition Revenue in Tumour-Induced Osteomalacia Business (2016-2021)
11.4.5 Kingdomway Nutrition Recent Development
11.5 Amgen
11.5.1 Amgen Company Details
11.5.2 Amgen Business Overview
11.5.3 Amgen Tumour-Induced Osteomalacia Introduction
11.5.4 Amgen Revenue in Tumour-Induced Osteomalacia Business (2016-2021)
11.5.5 Amgen Recent Development
11.6 Forgo Pharmaceuticals
11.6.1 Forgo Pharmaceuticals Company Details
11.6.2 Forgo Pharmaceuticals Business Overview
11.6.3 Forgo Pharmaceuticals Tumour-Induced Osteomalacia Introduction
11.6.4 Forgo Pharmaceuticals Revenue in Tumour-Induced Osteomalacia Business (2016-2021)
11.6.5 Forgo Pharmaceuticals Recent Development
11.7 Abbott
11.7.1 Abbott Company Details
11.7.2 Abbott Business Overview
11.7.3 Abbott Tumour-Induced Osteomalacia Introduction
11.7.4 Abbott Revenue in Tumour-Induced Osteomalacia Business (2016-2021)
11.7.5 Abbott Recent Development
11.8 Solvay
11.8.1 Solvay Company Details
11.8.2 Solvay Business Overview
11.8.3 Solvay Tumour-Induced Osteomalacia Introduction
11.8.4 Solvay Revenue in Tumour-Induced Osteomalacia Business (2016-2021)
11.8.5 Solvay Recent Development
11.9 GE Healthcare
11.9.1 GE Healthcare Company Details
11.9.2 GE Healthcare Business Overview
11.9.3 GE Healthcare Tumour-Induced Osteomalacia Introduction
11.9.4 GE Healthcare Revenue in Tumour-Induced Osteomalacia Business (2016-2021)
11.9.5 GE Healthcare Recent Development
11.10 Siemens
11.10.1 Siemens Company Details
11.10.2 Siemens Business Overview
11.10.3 Siemens Tumour-Induced Osteomalacia Introduction
11.10.4 Siemens Revenue in Tumour-Induced Osteomalacia Business (2016-2021)
11.10.5 Siemens Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Tumour-Induced Osteomalacia Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Drugs
Table 3. Key Players of Supplements
Table 4. Key Players of Surgery
Table 5. Key Players of Others
Table 6. Global Tumour-Induced Osteomalacia Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Tumour-Induced Osteomalacia Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Tumour-Induced Osteomalacia Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Tumour-Induced Osteomalacia Market Share by Regions (2016-2021)
Table 10. Global Tumour-Induced Osteomalacia Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Tumour-Induced Osteomalacia Market Share by Regions (2022-2027)
Table 12. Tumour-Induced Osteomalacia Market Trends
Table 13. Tumour-Induced Osteomalacia Market Drivers
Table 14. Tumour-Induced Osteomalacia Market Challenges
Table 15. Tumour-Induced Osteomalacia Market Restraints
Table 16. Global Tumour-Induced Osteomalacia Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Tumour-Induced Osteomalacia Market Share by Players (2016-2021)
Table 18. Global Top Tumour-Induced Osteomalacia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumour-Induced Osteomalacia as of 2020)
Table 19. Ranking of Global Top Tumour-Induced Osteomalacia Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Tumour-Induced Osteomalacia Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Tumour-Induced Osteomalacia Product Solution and Service
Table 23. Date of Enter into Tumour-Induced Osteomalacia Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Tumour-Induced Osteomalacia Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Tumour-Induced Osteomalacia Revenue Market Share by Type (2016-2021)
Table 27. Global Tumour-Induced Osteomalacia Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Tumour-Induced Osteomalacia Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Tumour-Induced Osteomalacia Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Tumour-Induced Osteomalacia Revenue Market Share by Application (2016-2021)
Table 31. Global Tumour-Induced Osteomalacia Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Tumour-Induced Osteomalacia Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Tumour-Induced Osteomalacia Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Tumour-Induced Osteomalacia Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Tumour-Induced Osteomalacia Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Tumour-Induced Osteomalacia Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Tumour-Induced Osteomalacia Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Tumour-Induced Osteomalacia Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Tumour-Induced Osteomalacia Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Tumour-Induced Osteomalacia Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Tumour-Induced Osteomalacia Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Tumour-Induced Osteomalacia Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Tumour-Induced Osteomalacia Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Tumour-Induced Osteomalacia Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Tumour-Induced Osteomalacia Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Tumour-Induced Osteomalacia Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Tumour-Induced Osteomalacia Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Tumour-Induced Osteomalacia Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Tumour-Induced Osteomalacia Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Tumour-Induced Osteomalacia Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Tumour-Induced Osteomalacia Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Tumour-Induced Osteomalacia Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Tumour-Induced Osteomalacia Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Tumour-Induced Osteomalacia Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Tumour-Induced Osteomalacia Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Tumour-Induced Osteomalacia Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Tumour-Induced Osteomalacia Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Tumour-Induced Osteomalacia Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Tumour-Induced Osteomalacia Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Tumour-Induced Osteomalacia Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Tumour-Induced Osteomalacia Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Tumour-Induced Osteomalacia Market Size by Country (2022-2027) & (US$ Million)
Table 63. Kyowa Kirin Company Details
Table 64. Kyowa Kirin Business Overview
Table 65. Kyowa Kirin Tumour-Induced Osteomalacia Product
Table 66. Kyowa Kirin Revenue in Tumour-Induced Osteomalacia Business (2016-2021) & (US$ Million)
Table 67. Kyowa Kirin Recent Development
Table 68. Taizhou Hisound Pharmaceutical Company Details
Table 69. Taizhou Hisound Pharmaceutical Business Overview
Table 70. Taizhou Hisound Pharmaceutical Tumour-Induced Osteomalacia Product
Table 71. Taizhou Hisound Pharmaceutical Revenue in Tumour-Induced Osteomalacia Business (2016-2021) & (US$ Million)
Table 72. Taizhou Hisound Pharmaceutical Recent Development
Table 73. Zhejiang Garden Biochemical High-tech Company Details
Table 74. Zhejiang Garden Biochemical High-tech Business Overview
Table 75. Zhejiang Garden Biochemical High-tech Tumour-Induced Osteomalacia Product
Table 76. Zhejiang Garden Biochemical High-tech Revenue in Tumour-Induced Osteomalacia Business (2016-2021) & (US$ Million)
Table 77. Zhejiang Garden Biochemical High-tech Recent Development
Table 78. Kingdomway Nutrition Company Details
Table 79. Kingdomway Nutrition Business Overview
Table 80. Kingdomway Nutrition Tumour-Induced Osteomalacia Product
Table 81. Kingdomway Nutrition Revenue in Tumour-Induced Osteomalacia Business (2016-2021) & (US$ Million)
Table 82. Kingdomway Nutrition Recent Development
Table 83. Amgen Company Details
Table 84. Amgen Business Overview
Table 85. Amgen Tumour-Induced Osteomalacia Product
Table 86. Amgen Revenue in Tumour-Induced Osteomalacia Business (2016-2021) & (US$ Million)
Table 87. Amgen Recent Development
Table 88. Forgo Pharmaceuticals Company Details
Table 89. Forgo Pharmaceuticals Business Overview
Table 90. Forgo Pharmaceuticals Tumour-Induced Osteomalacia Product
Table 91. Forgo Pharmaceuticals Revenue in Tumour-Induced Osteomalacia Business (2016-2021) & (US$ Million)
Table 92. Forgo Pharmaceuticals Recent Development
Table 93. Abbott Company Details
Table 94. Abbott Business Overview
Table 95. Abbott Tumour-Induced Osteomalacia Product
Table 96. Abbott Revenue in Tumour-Induced Osteomalacia Business (2016-2021) & (US$ Million)
Table 97. Abbott Recent Development
Table 98. Solvay Company Details
Table 99. Solvay Business Overview
Table 100. Solvay Revenue in Tumour-Induced Osteomalacia Business (2016-2021) & (US$ Million)
Table 101. Solvay Recent Development
Table 102. GE Healthcare Company Details
Table 103. GE Healthcare Business Overview
Table 104. GE Healthcare Tumour-Induced Osteomalacia Product
Table 105. GE Healthcare Revenue in Tumour-Induced Osteomalacia Business (2016-2021) & (US$ Million)
Table 106. GE Healthcare Recent Development
Table 107. Siemens Company Details
Table 108. Siemens Business Overview
Table 109. Siemens Tumour-Induced Osteomalacia Product
Table 110. Siemens Revenue in Tumour-Induced Osteomalacia Business (2016-2021) & (US$ Million)
Table 111. Siemens Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Tumour-Induced Osteomalacia Market Share by Type: 2020 VS 2027
Figure 2. Drugs Features
Figure 3. Supplements Features
Figure 4. Surgery Features
Figure 5. Others Features
Figure 6. Global Tumour-Induced Osteomalacia Market Share by Application: 2020 VS 2027
Figure 7. Laboratories Case Studies
Figure 8. Bone Scan Case Studies
Figure 9. Differential Diagnosis Case Studies
Figure 10. Others Case Studies
Figure 11. Tumour-Induced Osteomalacia Report Years Considered
Figure 12. Global Tumour-Induced Osteomalacia Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Tumour-Induced Osteomalacia Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Tumour-Induced Osteomalacia Market Share by Regions: 2020 VS 2027
Figure 15. Global Tumour-Induced Osteomalacia Market Share by Regions (2022-2027)
Figure 16. Global Tumour-Induced Osteomalacia Market Share by Players in 2020
Figure 17. Global Top Tumour-Induced Osteomalacia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumour-Induced Osteomalacia as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Tumour-Induced Osteomalacia Revenue in 2020
Figure 19. Global Tumour-Induced Osteomalacia Revenue Market Share by Type (2016-2021)
Figure 20. Global Tumour-Induced Osteomalacia Revenue Market Share by Type (2022-2027)
Figure 21. North America Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Tumour-Induced Osteomalacia Market Share by Type (2016-2027)
Figure 23. North America Tumour-Induced Osteomalacia Market Share by Application (2016-2027)
Figure 24. North America Tumour-Induced Osteomalacia Market Share by Country (2016-2027)
Figure 25. United States Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Tumour-Induced Osteomalacia Market Share by Type (2016-2027)
Figure 29. Europe Tumour-Induced Osteomalacia Market Share by Application (2016-2027)
Figure 30. Europe Tumour-Induced Osteomalacia Market Share by Country (2016-2027)
Figure 31. Germany Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Tumour-Induced Osteomalacia Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Tumour-Induced Osteomalacia Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Tumour-Induced Osteomalacia Market Share by Region (2016-2027)
Figure 41. China Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Tumour-Induced Osteomalacia Market Share by Type (2016-2027)
Figure 49. Latin America Tumour-Induced Osteomalacia Market Share by Application (2016-2027)
Figure 50. Latin America Tumour-Induced Osteomalacia Market Share by Country (2016-2027)
Figure 51. Mexico Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Tumour-Induced Osteomalacia Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Tumour-Induced Osteomalacia Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Tumour-Induced Osteomalacia Market Share by Country (2016-2027)
Figure 57. Turkey Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Tumour-Induced Osteomalacia Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Kyowa Kirin Revenue Growth Rate in Tumour-Induced Osteomalacia Business (2016-2021)
Figure 61. Taizhou Hisound Pharmaceutical Revenue Growth Rate in Tumour-Induced Osteomalacia Business (2016-2021)
Figure 62. Zhejiang Garden Biochemical High-tech Revenue Growth Rate in Tumour-Induced Osteomalacia Business (2016-2021)
Figure 63. Kingdomway Nutrition Revenue Growth Rate in Tumour-Induced Osteomalacia Business (2016-2021)
Figure 64. Amgen Revenue Growth Rate in Tumour-Induced Osteomalacia Business (2016-2021)
Figure 65. Forgo Pharmaceuticals Revenue Growth Rate in Tumour-Induced Osteomalacia Business (2016-2021)
Figure 66. Abbott Revenue Growth Rate in Tumour-Induced Osteomalacia Business (2016-2021)
Figure 67. Solvay Revenue Growth Rate in Tumour-Induced Osteomalacia Business (2016-2021)
Figure 68. GE Healthcare Revenue Growth Rate in Tumour-Induced Osteomalacia Business (2016-2021)
Figure 69. Siemens Revenue Growth Rate in Tumour-Induced Osteomalacia Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

以下、関連資料のご紹介

世界の腫瘍誘発性骨軟化症市場規模・現状・予測（2021年-2027年）

Global Tumour-Induced Osteomalacia Market Size, Status and Forecast 2021-2027
QYR2104Z5762 2021年4月 93Pages
QYResearch社発行の本調査資料では、腫瘍誘発性骨軟化症のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（医薬品、サプリメント、手術、その他）、用途別市場規模（検査室、骨スキャン、鑑別診断、その他）、主要地域別市場規模（北米、アメリカ、ヨー...

世界のオピオイド誘発性便秘（OIC）治療市場規模・現状・予測（2021年-2027年）

Global Opioid-Induced Constipation (OIC) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4281 2021年4月 96Pages
QYResearch社発行の本調査資料では、オピオイド誘発性便秘（OIC）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（経口、非経口（皮下注射））、用途別市場規模（ドラッグストア、独立型薬局、病院薬局）、主要地域別市場規模（北米、アメリカ...

世界のオピオイド誘発性便秘治療市場規模・現状・予測（2021年-2027年）

Global Opioid Induced Constipation Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4280 2021年4月 92Pages
QYResearch社発行の本調査資料では、オピオイド誘発性便秘治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（経口、非経口（皮下注射））、用途別市場規模（ドラッグストア、独立型薬局、病院薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッ...

世界の化学療法誘発性貧血市場規模・現状・予測（2021年-2027年）

Global Chemotherapy Induced Anemia Market Size, Status and Forecast 2021-2027
QYR2104Z1272 2021年4月 90Pages
QYResearch社発行の本調査資料では、化学療法誘発性貧血のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（軽度貧血、中等度貧血、重度貧血、致死的貧血）、用途別市場規模（病院、外来手術センター、専門クリニック、がん研究センター、がんリハビリセ...

世界の化学療法誘発性悪心・嘔吐（CINV）市場規模・現状・予測（2021年-2027年）

Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size, Status and Forecast 2021-2027
QYR2104Z1274 2021年4月 96Pages
QYResearch社発行の本調査資料では、化学療法誘発性悪心・嘔吐（CINV）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（CINV、PONV）、用途別市場規模（病院、外来手術センター、診断センター）、主要地域別市場規模（北米、アメリカ、ヨ...

世界の化学療法誘発性血小板減少症治療市場規模・現状・予測（2021年-2027年）

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z1275 2021年4月 95Pages
QYResearch社発行の本調査資料では、化学療法誘発性血小板減少症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（トロンボポエチン受容体作動薬、トロンボポエチン剤、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域...

世界の自家マトリックス誘導軟骨形成（AMIC）市場規模・現状・予測（2021年-2027年）

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size, Status and Forecast 2021-2027
QYR2104Z0525 2021年4月 99Pages
QYResearch社発行の本調査資料では、自家マトリックス誘導軟骨形成（AMIC）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ヒアルロン酸、コラーゲン、ポリエチレングリコール（PEG）、ポリ乳酸-co-グリコール酸（PGLA）、その他）、...

世界のオピオイド誘発性便秘市場規模・現状・予測（2021年-2027年）

Global Opioid-induced Constipation Market Size, Status and Forecast 2021-2027
QYR2104Z4282 2021年4月 126Pages
QYResearch社発行の本調査資料では、オピオイド誘発性便秘のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（固体、液体）、用途別市場規模（ドラッグストア、病院、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓...

世界のオピオイド誘発性便秘市場規模・現状・予測（2021年-2027年）

世界の化学療法誘発性末梢神経障害（CIPN）治療市場規模・現状・予測（2021年-2027年）

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z1273 2021年4月 131Pages
QYResearch社発行の本調査資料では、化学療法誘発性末梢神経障害（CIPN）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（カルシウムチャネルα2-デルタリガンド、抗うつ薬、オピオイド、その他）、用途別市場規模（プラチナ剤、タキサン、...

世界の腫瘍誘発性骨軟化症市場規模・現状・予測（2021年-2027年） Tumour-induced osteomalacia or oncogenic osteomalacia is a rare paraneoplastic syndrome of bone which consist of osteomalacia or rickets induced by phosphaturic mesenchymal tumour (PMT). Tumour-induced osteomalacia diagnosed with an elevated level of blood fibroblast growth factor 23 (FGF23), phosph…
世界の化学療法誘発性貧血市場規模・現状・予測（2021年-2027年） Anaemia is a frequent complication of malignancy and is aggravated by chemotherapy. The key factor contributing to the growth of the global chemotherapy induced anemia market is the increase in the occurrence of cancer and anemia among geriatric patients. Market Analysis and Insights: Global Chemoth…
世界のオピオイド誘発性便秘薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Opioid Induced Constipation Drugs Market The global Opioid Induced Constipation Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high da…
世界のオピオイド誘発性便秘薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Opioid Induced Constipation Drugs Market The global Opioid Induced Constipation Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high da…
世界のオピオイド誘発性便秘治療市場規模・現状・予測（2021年-2027年） There are multiple drugs in the pipeline for opioid induced constipation treatment. Upon approval, these drugs will face little competition in this market which is largely untapped. There have not been many stable choices in the pharmaceutical industry for opioid induced constipation treatment over …